Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression

Biological Psychiatry

Volumn 54, Issue 8, 2003, Pages 806-817

  Gelenberg, Alan J ^a,p   Trivedi, Madhukar H ^b   Rush, A John ^b   Thase, Michael E ^c   Howland, Robert ^c   Klein, Daniel N ^d   Kornstein, Susan G ^e   Dunner, David L ^f   Markowitz, John C ^g,h   Hirschfeld, Robert M A ⁱ   Keitner, Gabor I ^j   Zajecka, John ^k   Kocsis, James H ^g   Russell, James M ⁱ   Miller, Ivan ^j   Manber, Rachel ^l   Arnow, Bruce ^l   Rothbaum, Barbara ^m   Munsaka, Melvin ⁿ   Banks, Phillip ⁿ   Borian, Frances E ^o   Keller, Martin B ^j   more..

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

ⁱ UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^j BROWN UNIVERSITY   (United States)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l STANFORD UNIVERSITY   (United States)

^m EMORY UNIVERSITY   (United States)

ⁿ Statprobe   (United States)

^o BRISTOL MYERS SQUIBB   (United States)

^p UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

Chronic major depression; Combined treatment; Maintenance treatment; Nefazodone; Recurrence

Indexed keywords

ANTIDEPRESSANT AGENT; NEFAZODONE;

ABDOMINAL PAIN; ADULT; AGED; ANORGASMIA; ARTICLE; ASTHENIA; BACKACHE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; DYSPEPSIA; DYSTHYMIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FEMALE; FLU LIKE SYNDROME; HAMILTON SCALE; HEADACHE; HUMAN; INFECTION; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; PAIN; PHARYNGITIS; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUSITIS; SOMNOLENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 10744226599     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01971-6     Document Type: Article

References (56)

1. Albertsen P.C., Hanley J.A., Gleason D.F., Barry M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 280:1998;975-980.
2. Banbury M.K., Cosgrove D.M., White J.A., Blackstone E.H., Frater R.W., Okies J.E. Age and value size effect on the long-term durability of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg. 72:2001;753-757.
3. Beiser A., D'Agostino R.B., Seshadri S., Sullivan L.M., Wolf P.A. Computing estimates of incidence, including lifetime risk Alzheimer's disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro . Stat Med. 19:2000;1495-1522.
4. Blackburn I.M., Eunson K.M., Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. J Affect Disord. 10:1986;67-75.
5. Blackburn I.M., Moore R.G. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry. 171:1997;328-334.
6. Coppen A., Ghose K., Montgomery S., Rama Rau V.A., Balley J., Jorgensen A. Continuation therapy with amitriptyline in depression. Br J Psychiatry. 133:1978;28-33.
7. David H.A., Moeschberger M.L. The Theory of Competing Risks. 1978;Griffin, London.
8. Clinical Practice Guideline. Number 5 Depression in Primary Care, Volume 2. Treatment of Major Depression . 1993;U.S. Dept. of Health and Human Services, Public Health Service, Rockville, MD. AHCPR Publication No. 93-0551.
9. Dilsaver S.C., Greden J.F. Antidepressant withdrawal phenomena. Biol Psychiatry. 19:1984;237-256.
10. Doogan D.P., Caillard V. Sertraline in the prevention of depression. Br J Psychiatry. 160:1992;217-222.
11. Evans M.D., Hollon S.D., DeRubeis R.J., Piasecki J.M., Garvey M.J., Grove W.M., et al. Differential relapse following cognitive therapy, pharmacotherapy, and combined cognitive-pharmacotherapy for depression. Arch Gen Psychiatry. 49:1992;802-808.
12. Fava G.A., Rafanelli C., Grandi S., Conti S., Belluardo P. Prevention of recurrent depression with cognitive behavioral therapy Preliminary findings . Arch Gen Psychiatry. 55:1988;816-820.
13. Fawcett J., Epstein P., Fiester S.J., Elkin I., Autry J.H. Clinical management - imipramine/placebo administration manual. Psychopharmacology Bull. 23:1987;309-324.
14. Feiger A.D., Bielski R.J., Bremner J., Heiser J.F., Trivedi M., Wilcox C.S., et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacology. 14:1999;19-28.
15. Frank E., Kupfer D.J., Perel J.M., Cornes C., Jarrett D.B., Mallinger A.G., et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 47:1990;1093-1099.
16. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder Remission, recovery, relapse, and recurrence . Arch Gen Psychiatry. 46:1991;851-855.
17. Gaynor J.J., Feuer E.J., Tan C.C., Wu D.H., Little C.R., Straus D.J., et al. On the use of cause-specific failure and conditional failure probabilities Examples from clinical oncology data . J Am Stat Association. 88:1993;400-409.
18. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks New representations of old estimators . Stat Med. 18:1999;695-706.
19. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 6:1967;278-296.
20. Hays R.D., Wells K.B., Sherbourne C.D., Rogers W., Spritzer K. Functioning and well-being outcomes of patients with depression compared with chronic general medical illness. Arch Gen Psychiatry. 52:1995;11-19.
21. Hochstrasser B., Isaksen P.M., Koponen H., Lauritzenm L., Mahnert F.A., Rouillon F., et al. Prophylactic effect of citalopram in unipolar recurrent depression. Br J Psychiatry. 178:2001;304-310.
22. Howland R.H. Chronic depression. Hosp Community Psychiatry. 44:1993;633-639.
23. Jarrett R.B., Basco M.R., Risser R., Ramanan J., Marwill M., Kraft D., et al. Is there a role for continuation phase cognitive therapy for depressed outpatients? J Consult Clin Psychol. 66:1998;1036-1040.
24. Keller M.B., Kocsis J.H., Thase M.E., Gelenberg A.J., Rush A.J., Koran L., et al. Maintenance phase efficacy of sertraline for chronic depression. A randomized controlled trial. JAMA. 280:1998;1665-1672.
25. Keller M.B., Lavori P.W., Mueller T.I., Endicott J., Coryell W., Hirschfeld R.M., et al. Time to recovery, chronicity and levels of psychopathology in major depression A 5-year prospective follow-up of 431 subjects . Arch Gen Psychiatry. 49:1992;809-816.
26. Keller M.B., McCullough J.P., Klein D.N., Arnow B., Dunner D.L., Gelenberg A.J., et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Eng J Med. 342:2000;1462-1470.
27. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States Results from the National Comorbidity Survey . Arch Gen Psychiatry. 51:1994;8-19.
28. Klein D.N., Norden K.A., Ferro T., Leader J.B., Kasch K.L., Klein L.M., et al. Thirty-month naturalistic follow-up study of early-onset dysthymic disorder Course, diagnostic stability, and prediction of outcome . J Abnorm Psychol. 107:1998;338-348.
29. Kocsis J.H., Friedman R.A., Markowitz J.C., Leon A.C., Miller N.L., Gniwesch L., et al. Maintenance therapy for chronic depression A controlled clinical trial of desipramine . Arch Gen Psychiatry. 53:1996;769-774.
30. Kovacs M., Rush A.T., Beck A.T., Hollon S.D. Depressed outpatients treated with cognitive therapy or pharmacotherapy A one-year follow-up . Arch Gen Psychiatry. 38:1981;33-39.
31. Kupfer D.J. Long-term treatment of depression. J Clin Psychiatry. 52:1991;28-34.
32. Linden M., Gother H., Dittman R.W., Schaaf B. Early termination of antidepressant drug treatment. J Clin Psychopharmacol. 20:2000;523-530.
33. Maj M., Veltro F., Pirozzi R., Lobrace S., Magliana L. Pattern of recurrence of illness after recovery from an episode of major depression A prospective study . Am J Psychiatry. 149:1992;795-800.
34. Michelson D., Fava M., Amsterdam J., Apter J., Londborg P., Tamura R., et al. Interruption of selective serotonin reuptake inhibitor treatment Double-blind, placebo-controlled trial . Br J Psychiatry. 176:2000;363-368.
35. Miller I.W., Keitner G.I., Schatzberg A.F., Klein D.N., Thase M.E., Rush A.J., et al. The treatment of chronic depression, part 3 Psychosocial functioning before and after treatment with sertraline or imipramine . J Clin Psychiatry. 59:1998;608-619.
36. Mindham R.H.S., Howland C., Shepherd M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med. 3:1973;5-17.
37. Montgomery S.A., Dufour H., Brion S., Gailledreau J., Laqueille X., Ferrey G., et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry. 153:(suppl 3):1988;69-76.
38. Montgomery S.A., Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol. 8:1993;189-195.
39. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors Global Burden of Disease Study . Lancet. 349:1997;1436-1442.
40. Paykel E.S., Scott J., Teasdale J.D., Johnson A.L., Garland A., Moore R., et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry. 56:1999;829-835.
41. Pepe M.S., Fleming T.R. Weighted Kaplan-Meier statistics - a class of distance tests for censored survival data. Biometrics. 45:1989;497-507.
42. Pollack H.A., Frohna J.G. A competing risk model of sudden infant death syndrome incidence in two US birth cohorts. J Pediatrics. 138:2001;661-667.
43. Prentice R.L., Kalbfleisch J.D., Peterson A.V., Flournoy N., Farewell V.T., Breslow N.E. The analysis of failure times in the presence of competing risks. Biometrics. 34:1978;541-554.
44. Prien R.F., Kupfer D.J., Mansky P.A., Small J.G., Tuason V.B., Voss C.B., et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and lithium carbonate-imipramine combination . Arch Gen Psychiatry. 41:1984;1096-1104.
45. Robins L., Regier D.A. Psychiatric Disorders in America. 1991;Free Press, New York.
46. Robinson D.S., Roberts D.L., Smith J.M., Stringfellow J.C., Kaplita S.B., Seminara J.A., et al. The safety profile of nefazodone. J Clin Psychiatry. 57:(suppl 2):1996;31-38.
47. Rosen R.C., Lane R.M., Menza M. Effects of SSRIs on sexual function A critical review . J Clin Psychopharmacol. 19:1999;67-85.
48. Rosenbaum J.F., Fava M., Hoog S.L., Ascroft R.C., Krebs W.B. Selective serotonin reuptake inhibitor discontinuation syndrome A randomized clinical trial . Biol Psychiatry. 44:1998;77-87.
49. Rush A.J., Koran L.M., Keller M.B., Markowitz J.C., Harrison W.M., Miceli R.J., et al. The treatment of chronic depression, part 1 Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies . J Clin Psychiatry. 59:1998;589-597.
50. Settle E.C. Antidepressant side effects Issues and options . J Clin Psychiatry. 10:1992;48-61.
51. Sussman N., Ginsberg D.L., Bikoff J. Effects of nefazodone on body weight A pooled analyses of selective serotonin reuptake inhibitor- and imipramine-controlled trials . J Clin Psychiatry. 62:2001;256-260.
52. Thase M.E., Nierenberg A.A., Keller M.B., Panagides J. Efficacy of mirtazapine for prevention of depressive relapse A placebo-controlled double-blind trial of recently remitted high-risk patients . J Clin Psychiatry. 62:2001;782-788.
53. Versiani M., Mehilane L., Gaszner P., Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry. 60:1999;400-406.
54. Weissman M.M., Leaf P.J., Bruce M.L., Florio L. The epidemiology of dysthymia in five communities Rates, risks, comorbidity, and treatment . Am J Psychiatry. 145:1988;815-819.
55. Wells K.B., Burnam A., Rogers W., Hays R., Camp P. The course of depression in adult outpatients Results from the medical outcomes study . Arch Gen Psychiatry. 49:1992;788-801.
56. Yan Y., Moore R.D., Hoover D.R. Competing risk adjustment reduces overestimation of opportunistic infection rates in AIDS. J Clin Epidemiol. 53:2000;817-822.